Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EBITDA: 2022-2025

Historic EBITDA for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$43.9 million.

  • Entrada Therapeutics' EBITDA fell 244.93% to -$43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.8 million, marking a year-over-year decrease of 283.99%. This contributed to the annual value of $65.4 million for FY2024, which is 1575.03% up from last year.
  • Entrada Therapeutics' EBITDA amounted to -$43.9 million in Q3 2025, which was down 1.79% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' EBITDA's 5-year high stood at $54.9 million during Q2 2024, with a 5-year trough of -$43.9 million in Q3 2025.
  • Its 3-year average for EBITDA is -$3.9 million, with a median of -$8.9 million in 2023.
  • In the last 5 years, Entrada Therapeutics' EBITDA soared by 538.39% in 2024 and then plummeted by 244.93% in 2025.
  • Over the past 4 years, Entrada Therapeutics' EBITDA (Quarterly) stood at -$23.9 million in 2022, then surged by 63.02% to -$8.9 million in 2023, then skyrocketed by 101.31% to $116,000 in 2024, then tumbled by 244.93% to -$43.9 million in 2025.
  • Its last three reported values are -$43.9 million in Q3 2025, -$43.1 million for Q2 2025, and -$16.9 million during Q1 2025.